NO20081067L - Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav - Google Patents
Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt deravInfo
- Publication number
- NO20081067L NO20081067L NO20081067A NO20081067A NO20081067L NO 20081067 L NO20081067 L NO 20081067L NO 20081067 A NO20081067 A NO 20081067A NO 20081067 A NO20081067 A NO 20081067A NO 20081067 L NO20081067 L NO 20081067L
- Authority
- NO
- Norway
- Prior art keywords
- omega
- fatty acids
- channel blockers
- dihydropyndincalcium
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70300205P | 2005-07-28 | 2005-07-28 | |
PCT/US2006/029217 WO2007016256A2 (en) | 2005-07-28 | 2006-07-28 | Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20081067L true NO20081067L (no) | 2008-04-18 |
Family
ID=37709175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20081067A NO20081067L (no) | 2005-07-28 | 2008-02-28 | Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav |
Country Status (12)
Country | Link |
---|---|
US (1) | US20070196465A1 (zh) |
EP (1) | EP1919285A2 (zh) |
JP (1) | JP2009502950A (zh) |
KR (1) | KR20080030691A (zh) |
CN (1) | CN101252837A (zh) |
AU (1) | AU2006275784A1 (zh) |
BR (1) | BRPI0614417A2 (zh) |
CA (1) | CA2616806A1 (zh) |
EA (1) | EA200800451A1 (zh) |
MX (1) | MX2008001282A (zh) |
NO (1) | NO20081067L (zh) |
WO (1) | WO2007016256A2 (zh) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007103557A2 (en) * | 2006-03-09 | 2007-09-13 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
ES2579229T3 (es) | 2007-03-13 | 2016-08-08 | Jds Therapeutics, Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
KR101946977B1 (ko) * | 2008-08-01 | 2019-05-21 | 치에시 파마슈티시 에스.피.아. | 약제학적 조성물 및 이를 안정화시키는 방법 |
CA3108961A1 (en) * | 2008-08-01 | 2010-02-04 | Hospira, Inc. | Pharmaceutical compositions comprising clevidipine and methods for producing low impurity concentrations of the same |
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
CA3089847C (en) | 2009-02-10 | 2024-04-09 | Amarin Pharmaceuticals Ireland Limited | Use of eicosapentaenoic acid to treat hypertriglyceridemia |
NZ771180A (en) | 2009-04-29 | 2022-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
ES2856959T3 (es) | 2009-06-15 | 2021-09-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina |
EP2480248B1 (en) | 2009-09-23 | 2015-09-02 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
ES2363964B1 (es) * | 2009-11-20 | 2012-08-22 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados. |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물 |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
EP2861227A4 (en) | 2012-06-17 | 2016-01-27 | Matinas Biopharma Inc | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3413900A1 (en) | 2016-02-11 | 2018-12-19 | Nutrition 21, LLC | Chromium containing compositions for improving health and fitness |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5186942A (en) * | 1989-01-30 | 1993-02-16 | Alza Corporation | Nicardipine therapy |
US5162325A (en) * | 1991-05-07 | 1992-11-10 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
KR20040025889A (ko) * | 2001-01-26 | 2004-03-26 | 쉐링 코포레이션 | 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물 |
JP4421804B2 (ja) * | 2002-03-25 | 2010-02-24 | 日本メナード化粧品株式会社 | 高血圧抑制剤 |
US7759507B2 (en) * | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
US8784886B2 (en) * | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
-
2006
- 2006-07-28 WO PCT/US2006/029217 patent/WO2007016256A2/en active Application Filing
- 2006-07-28 MX MX2008001282A patent/MX2008001282A/es unknown
- 2006-07-28 JP JP2008524148A patent/JP2009502950A/ja active Pending
- 2006-07-28 CA CA002616806A patent/CA2616806A1/en not_active Abandoned
- 2006-07-28 KR KR1020087004930A patent/KR20080030691A/ko not_active Application Discontinuation
- 2006-07-28 AU AU2006275784A patent/AU2006275784A1/en not_active Abandoned
- 2006-07-28 EP EP06788670A patent/EP1919285A2/en not_active Withdrawn
- 2006-07-28 CN CNA2006800318145A patent/CN101252837A/zh active Pending
- 2006-07-28 US US11/494,799 patent/US20070196465A1/en not_active Abandoned
- 2006-07-28 BR BRPI0614417-9A patent/BRPI0614417A2/pt not_active Application Discontinuation
- 2006-07-28 EA EA200800451A patent/EA200800451A1/ru unknown
-
2008
- 2008-02-28 NO NO20081067A patent/NO20081067L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MX2008001282A (es) | 2008-03-24 |
BRPI0614417A2 (pt) | 2011-03-29 |
KR20080030691A (ko) | 2008-04-04 |
CN101252837A (zh) | 2008-08-27 |
JP2009502950A (ja) | 2009-01-29 |
WO2007016256A2 (en) | 2007-02-08 |
EA200800451A1 (ru) | 2008-08-29 |
AU2006275784A1 (en) | 2007-02-08 |
WO2007016256A3 (en) | 2007-07-12 |
EP1919285A2 (en) | 2008-05-14 |
US20070196465A1 (en) | 2007-08-23 |
CA2616806A1 (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20081067L (no) | Behandling med dihydropyndinkalsiumkanalblokkere og omega 3-fettsyrer, og et kombinasjonsprodukt derav | |
NO20080855L (no) | Behandling med azetidinon-baserte kolesterol absorpsjonsinhibitorer og omega-3 fettsyrer og et kombinasjonsprodukt derav | |
EA200970374A1 (ru) | Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом | |
ATE344226T1 (de) | Aspirin-ausgelöste lipidmediatoren | |
IS7648A (is) | Dífenýlasetídínónafleiður til að meðhöndla fituefnaskiptasjúkdóma | |
CY1115059T1 (el) | Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα | |
BRPI0520669A2 (pt) | dosagem farmacêutica que reduz o efeito do alimento encontrado para administração de atorvastatina | |
CO2018013077A2 (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas | |
CL2008003486A1 (es) | 6-oxo-1,6-dihidropiridazinas; sus usos para tratar un trastorno hiperproliferativo; la composición farmacéutica que las contiene; y sus procesos de preparación (div. sol. 1168-06). | |
CL2004002015A1 (es) | Derivados de amida, productos que las contienen, utiles para modificar el sabor de alimentos y medicamentos. | |
ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
UY30710A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales ciclohexilo, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso. | |
NO20076687L (no) | Oral doseringsform | |
CL2008002394A1 (es) | Depsipeptido ciclico, o derivados, inhibidores de calicreína 7, obtenidos desde chondromyces crocatus, metodo de obtencion y usos terapeuticos. | |
UY30468A1 (es) | Compuestos quimicos. | |
GT200600463A (es) | Derivados de carbamoilbenzotriazol como inhibidores de lipasas y fosfolipasas | |
BRPI0416268A (pt) | composições de delta-9-thc e métodos para o tratamento de sintomas associados à esclerose múltipla | |
CY1117184T1 (el) | ΤΕΛΕΣΤΕΣ β-ΑΡΡΕΣΤΙΝΗΣ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΚΑΙ ΜΕΘΟΔΟΙΧΡΗΣΗΣ ΑΥΤΩΝ | |
CL2007003018A1 (es) | Metodo para administrar nutricion alimentada por tubo a un paciente anciano; y producto de nutricion. | |
CL2004001004A1 (es) | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. | |
PA8531701A1 (es) | Derivados de pirimidina | |
DK1589834T3 (da) | Enteral komposition til forebyggelse og/eller behandling af sepsis | |
AR067351A1 (es) | Combinacion de picotamida con nafronil | |
PA8579401A1 (es) | Derivados de 2,3-dihidro-isoindol-1-ona como inhibidores de mao-b | |
UY28951A1 (es) | Pequenas moleculas para el tratamiento de hipercolesterolemia y enfermedades relacionadas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |